Form 4: COMPASS Pathways CMO Acquires 170,600 Stock Options
Insider Transaction Report
COMPASS Pathways' Chief Medical Officer, Guy Goodwin, acquired 170,600 stock options with varying exercise prices and vesting schedules.
Summary
- Guy Goodwin, Chief Medical Officer of COMPASS Pathways plc (CMPS), acquired a total of 170,600 derivative securities in the form of stock options.
- One tranche of 55,000 share options was acquired with an exercise price of $0.01 per share.
- These 55,000 options will vest in four equal annual installments, commencing on March 26, 2027, and expire on March 25, 2036.
- A second tranche of 115,600 share options was acquired with an exercise price of $5.64 per share.
- These 115,600 options will vest in forty-eight equal monthly installments, beginning on April 26, 2026, and also expire on March 25, 2036.
- All acquired options were reported as directly beneficially owned by Mr. Goodwin.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as insider acquisition of options generally indicates confidence in the company's future prospects, particularly with a very low exercise price for a significant portion of the options.
Positives
- The acquisition of 170,600 stock options by a key executive like the Chief Medical Officer can signal management's confidence in the company's future performance.
- One tranche of 55,000 options has a nominal exercise price of $0.01, which is highly favorable for the executive and aligns incentives with long-term share price appreciation.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transactions.
Industry Context
StockSavvy.ai notes that insider option grants are a common component of executive compensation packages in the biotechnology and pharmaceutical sectors, designed to align management's interests with shareholder value creation. The vesting schedules indicate a long-term retention and performance incentive.
Stakeholder Impact
- Shareholders: The acquisition of options by a key executive aligns management's incentives with shareholder interests, potentially leading to decisions that enhance long-term stock value.
- Employees: This transaction is part of executive compensation, which can influence overall compensation strategies and morale within the company.
Key Dates
| Date | Description |
|---|---|
| 03/26/2026 | Date of earliest transaction for the acquisition of both tranches of share options. |
| 04/26/2026 | Start date for the forty-eight equal monthly vesting installments for the 115,600 share options. |
| 03/26/2027 | Start date for the four equal annual vesting installments for the 55,000 share options. |
| 03/25/2036 | Expiration date for both tranches of acquired share options. |
| 03/27/2026 | Date the Form 4 was signed by Power of Attorney for Guy Goodwin. |
Keywords
COMPASS Pathways, CMPS, Stock Options, Insider Trading, Executive Compensation, Form 4, Derivative Securities, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.